Evidence map›Paper›PMID 38769687›Full record

ArticleJournal of breast cancer2024

Neoadjuvant Chemotherapy Is Effective in Those Infected With SARS-CoV-2: The Real-World Experience of a Large Chinese Breast Cancer Center.

Teng Ma, Tianyi Ma, Lulu Wang, Haibo Wang

Abstract read
In one paragraph

Article in Journal of breast cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Teng Ma *Breast Disease Center, Affiliated Hospital of Qingdao University, Qingdao, China.ORCID https://orcid.org/0000-0003-1512-8018
Tianyi Ma *Breast Disease Center, Affiliated Hospital of Qingdao University, Qingdao, China.ORCID https://orcid.org/0000-0002-8351-8950
Lulu WangDepartment of Cardiovascular Surgery, Affiliated Hospital of Qingdao University, Qingdao, China.ORCID https://orcid.org/0000-0003-2453-3701
Haibo WangBreast Disease Center, Affiliated Hospital of Qingdao University, Qingdao, China. hbwang66@qdu.edu.cn.ORCID https://orcid.org/0000-0002-5585-704X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeDuring the major shift in China's policies on coronavirus disease 2019 (COVID-19), many residents will be infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) over a short period, including a few patients with breast cancer undergoing neoadjuvant chemotherapy (NAC). Moreover, it is unknown whether this comorbidity affects the efficacy of NAC for breast cancer and the patient's psychological state and quality of life (QOL). This study aims to answer these questions.

methodsThe clinical data of 2,793 patients with breast cancer who received NAC at The Affiliated Hospital of Qingdao University were retrospectively collected. The infected and non-infected groups were divided according to whether they were infected with COVID-19 during NAC. Propensity score matching was used to reduce patient selection bias. The effectiveness, psychological well-being, and QOL of the two groups were compared.

resultsNo discernible differences were observed in the pathological complete response rates (

conclusionWith timely treatment and effective medical management, SARS-CoV-2 does not appear to affect the efficacy of NAC; however, it can significantly affect the QOL of patients and increase their psychological distress. Therefore, in addition to a timely assessment of the efficacy of NAC, it is necessary to dynamically understand the patient's psychological state and QOL.

Indexed as

AnxietyCOVID-19DepressionNeoadjuvant TherapyQuality of Life

Identifiers

PMID38769687
PMCPMC11221209

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.